Clinical Trials Logo

Peripheral T-cell Lymphoma clinical trials

View clinical trials related to Peripheral T-cell Lymphoma.

Filter by:

NCT ID: NCT02753543 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Start date: November 2015
Phase: Phase 2
Study type: Interventional

This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of chemotherapy in interim evaluation.

NCT ID: NCT02512497 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Start date: December 8, 2017
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of romidepsin that can be given with this combination. The safety of this combination and the safety of giving romidepsin after a stem cell transplant will also be studied. This is an investigational study. Romidepsin is FDA approved and commercially available for the treatment of CTCL in patients who have received at least 1 systemic (affecting the whole body) therapy before. Busulfan and fludarabine are FDA approved and commercially available for use with a stem cell transplant. The use of the combination of romidepsin, busulfan, and fludarabine to treat the type of leukemia or lymphoma you have is considered investigational. Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT02495415 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study addresses the hypothesis that intermittent treatment with fenretinide intravenous emulsion will induce objective responses in patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL) who have failed at least one prior systemic therapy and will result in acceptable toxicities.

NCT ID: NCT02445404 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

Start date: September 23, 2015
Phase: Phase 2
Study type: Interventional

This study is a Randomized Phase II Study to Compare Efficacy of CHOP versus Fractionated ICED in Transplant-eligible Patients with Previously Untreated Peripheral T-cell Lymphoma.

NCT ID: NCT01664975 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Treatment of Peripheral T-cell Lymphoma

Start date: August 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabine,cisplatin,Prednisone ,Thalidomide ) for patients with Peripheral T-cell lymphoma.

NCT ID: NCT01470066 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas

Start date: August 2004
Phase: N/A
Study type: Observational

Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computerized tomography (CT) scan has emerged as a powerful prognostic tool in predicting treatment outcome in Hodgkin's lymphoma (HL) and diffuse large B cell lymphoma (DLBCL), the positive predictive value (PPV) of interim PET/CT scanning has not been determined in patients with peripheral T cell lymphoma (PTCL). The sequential interim PET/CT will be prospectively investigated to determine whether it provided additional prognostic information and could be a positive predictable value for the treatment of PTCL.